TABLE OF CONTENTS
| | | | Volume 24, Issue 5 (May 2017) | | In this issue Review Original Articles
Also new AOP | | | | | Advertisement | | | | | | Review | Top | | The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trialsL Ansari, F Shiehzadeh, Z Taherzadeh, S Nikoofal-Sahlabadi, A A Momtazi-borojeni, A Sahebkar and S Eslami Cancer Gene Ther 2017 24: 189-193; advance online publication, April 14, 2017; 10.1038/cgt.2017.9 Abstract | Full Text | | Original Articles | Top | | Her-2 expression regulated by downregulation of miR-9 and which affects chemotherapeutic effect in breast cancerG Sun, L Sun, Y Liu, H Xing and K Wang Cancer Gene Ther 2017 24: 194-202; advance online publication, March 31, 2017; 10.1038/cgt.2014.82 Abstract | Full Text | | | | Customized laboratory TLR4 and TLR2 detection method from peripheral human blood for early detection of doxorubicin-induced cardiotoxicityA L Pop-Moldovan, N -M Trofenciuc, D A Dărăbanţiu, C Precup, H Branea, R Christodorescu and M Puşchiţă Cancer Gene Ther 2017 24: 203-207; advance online publication, March 3, 2017; 10.1038/cgt.2017.4 Abstract | Full Text | | | | MiR-216b increases cisplatin sensitivity in ovarian cancer cells by targeting PARP1Y Liu, Z Niu, X Lin and Y Tian Cancer Gene Ther 2017 24: 208-214; advance online publication, March 10, 2017; 10.1038/cgt.2017.6 Abstract | Full Text | | | | Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in ChinaH-W Wang, Z-K Xu, Y Song and Y-G Liu Cancer Gene Ther 2017 24: 215-220; advance online publication, April 14, 2017; 10.1038/cgt.2017.7 Abstract | Full Text | | | | lncRNA-HIT promotes cell proliferation of non-small cell lung cancer by association with E2F1L Yu, F Fang, S Lu, X Li, Y Yang and Z Wang Cancer Gene Ther 2017 24: 221-226; advance online publication, April 21, 2017; 10.1038/cgt.2017.10 Abstract | Full Text | | | | In vitro detection of cholangiocarcinoma cells using a fluorescent protein-expressing oncolytic herpes virusR J S Coelen, M J de Keijzer, R Weijer, V V Loukachov, J K Wiggers, F P J Mul, A C W A van Wijk, Y Fong, M Heger and T M van Gulik Cancer Gene Ther 2017 24: 227-232; advance online publication, April 14, 2017; 10.1038/cgt.2017.11 Abstract | Full Text | | | | | | | | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com | | | | | | | | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Cancer Gene Therapy. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved. | | | | |
No comments:
Post a Comment